Dr. Karin Denton:

It compares well with cervical cancer prevention strategies that are operable in many other countries. When it comes down to it, it is an organised screening programme with a high uptake and with strong pathways to make sure women are followed throughout their lives so that it is not just a series of one-off tests. There are not so many countries that have an organised screening programme like that. It is starting off in a positive position and, as Dr. Scally said, the moves to improve the sensitivity of the test by moving towards HPV screening as a primary screening test are under way as I understand it. That will lead to further improvements in the international league tables. Ultimately, it compares well with what is available in many other European countries as well as more widely.